<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.109329</article-id><article-id pub-id-type="publisher-id">ACM-37838</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200900000_37142841.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  恶性肿瘤相关凝血功能的研究进展
  Advances in Research on Coagulation Function Associated with Malignant Tumors
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>跳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>卫卫</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院，肿瘤科，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>09</month><year>2020</year></pub-date><volume>10</volume><issue>09</issue><fpage>2180</fpage><lpage>2184</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    恶性肿瘤在进展的时候，往往伴随着凝血功能的异常。肿瘤细胞通过影响机体内凝血与抗凝血之间的动态平衡，从而进一步影响肿瘤细胞的增殖、浸润、侵袭、转移。其中，血小板、纤维蛋白原、D-二聚体三项指标在临床中不仅容易获取，而且特异度较高。因此，尽早发现凝血功能异常，对诊断恶性肿瘤有着重要意义。本文就恶性肿瘤凝血功能的研究进展作一简要综述。
    Malignant tumor is often accompanied by abnormal coagulation function. Tumor cells further affect the proliferation, invasion, invasion and metastasis of tumor cells by affecting the dynamic balance between coagulation and anticoagulation. Among them, platelet, fibrinogen and D-dimer are not only easy to obtain in clinic, but also have high specificity. Therefore, early detection of coagulation dysfunction is of great significance for the diagnosis of malignant tumors. In this paper, the research progress of coagulation function in malignant tumor is reviewed. 
  
 
</p></abstract><kwd-group><kwd>恶性肿瘤，血小板，纤维蛋白原，D-二聚体, Malignant Tumor</kwd><kwd> Platelet</kwd><kwd> Fibrinogen</kwd><kwd> D-Dimer</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>恶性肿瘤在进展的时候，往往伴随着凝血功能的异常。肿瘤细胞通过影响机体内凝血与抗凝血之间的动态平衡，从而进一步影响肿瘤细胞的增殖、浸润、侵袭、转移。其中，血小板、纤维蛋白原、D-二聚体三项指标在临床中不仅容易获取，而且特异度较高。因此，尽早发现凝血功能异常，对诊断恶性肿瘤有着重要意义。本文就恶性肿瘤凝血功能的研究进展作一简要综述。</p></sec><sec id="s2"><title>关键词</title><p>恶性肿瘤，血小板，纤维蛋白原，D-二聚体</p></sec><sec id="s3"><title>Advances in Research on Coagulation Function Associated with Malignant Tumors</title><p>Tiao Zhang, Weiwei Yang</p><p>Department of Oncology, Affiliated Hospital of Yan’an University, Yan’an Shaanxi</p><p><img src="//html.hanspub.org/file/49-1571569x4_hanspub.png" /></p><p>Received: Sep. 4<sup>th</sup>, 2020; accepted: Sep. 18<sup>th</sup>, 2020; published: Sep. 25<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/49-1571569x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Malignant tumor is often accompanied by abnormal coagulation function. Tumor cells further affect the proliferation, invasion, invasion and metastasis of tumor cells by affecting the dynamic balance between coagulation and anticoagulation. Among them, platelet, fibrinogen and D-dimer are not only easy to obtain in clinic, but also have high specificity. Therefore, early detection of coagulation dysfunction is of great significance for the diagnosis of malignant tumors. In this paper, the research progress of coagulation function in malignant tumor is reviewed.</p><p>Keywords:Malignant Tumor, Platelet, Fibrinogen, D-Dimer</p><disp-formula id="hanspub.37838-formula47"><graphic xlink:href="//html.hanspub.org/file/49-1571569x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/49-1571569x7_hanspub.png" /> <img src="//html.hanspub.org/file/49-1571569x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>近年来，虽然人们健康体检意识提高了，但是恶性肿瘤的发病率仍逐年递增。据GLOBOCAN 2018年估计数据表明，2018年将有1810万新的癌症病例和960万人死于癌症。癌症已成为全世界发病率和死亡率的一个重要原因 [<xref ref-type="bibr" rid="hanspub.37838-ref1">1</xref>]。然而，早期肿瘤没有明显临床症状，大多数确诊时已属中晚期。因此，早发现、早诊断、早治疗，对于癌症患者来说极其重要。相关研究显示，约95%的恶性肿瘤患者存在凝血指标的异常，这种异常促进了恶性肿瘤的发生发展、转移及预后，尤其是肺癌患者 [<xref ref-type="bibr" rid="hanspub.37838-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.37838-ref3">3</xref>]。因此研究恶性肿瘤与凝血功能的关系具有重要意义。临床上常见凝血指标有纤维蛋白原、D-二聚体、血小板、凝血酶原时间、部分凝血活酶时间、凝血酶时间、国际标准化比值等。本文将对血小板、纤维蛋白原、D-二聚体在肿瘤患者中的研究进展进行综述。</p></sec><sec id="s6"><title>2. 血小板在恶性肿瘤诊断、监测、预后中的研究进展</title><p>血小板是成熟的巨核细胞胞浆裂解后脱落下来的小块胞质，其特征是无细胞，有细胞器，是人体中数目最多、形态最小的血细胞 [<xref ref-type="bibr" rid="hanspub.37838-ref4">4</xref>]。血小板主要参与机体的凝血、止血和修补破损的血管。自1872年国外学者首次在恶性肿瘤患者中发现血小板数量升高后，越来越多的学者开始研究血小板在恶性肿瘤患者血液中的变化。有研究发现，血小板可通过多种方式促进肿瘤细胞生长、转移、逃避免疫监视，提高侵袭能力和血管生成等 [<xref ref-type="bibr" rid="hanspub.37838-ref5">5</xref>]，因此血小板在肿瘤细胞的发生发展中也起着重要作用。相关研究表明，血小板的升高与非小细胞肺癌有着密切联系，20%~30%的非小细胞肺癌患者血小板会升高 [<xref ref-type="bibr" rid="hanspub.37838-ref6">6</xref>]。还有研究报道，血小板增多可作为评估结直肠癌患者病情进展及预后的指标之一 [<xref ref-type="bibr" rid="hanspub.37838-ref7">7</xref>]。黄远玲等发现在胃癌患者中，血小板还可通过释放颗粒蛋白，与活化的血小板、前列腺素作用于血管，增加了血管通透性，促使肿瘤周围组织降解而转移 [<xref ref-type="bibr" rid="hanspub.37838-ref8">8</xref>]。申太峰等研究提示宫颈癌患者血小板升高与疾病晚期、脉管瘤栓转移、非鳞状细胞癌及深肌层浸润相关 [<xref ref-type="bibr" rid="hanspub.37838-ref9">9</xref>]。目前恶性肿瘤患者血小板增多的机制尚不清楚，可能与以下几个方面相关：1) 恶性肿瘤细胞内的促进肿瘤生长的细胞因子增多，同样能特异性刺激血小板增多，如IL-1、IL-3、肿瘤坏死因子-α等 [<xref ref-type="bibr" rid="hanspub.37838-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.37838-ref11">11</xref>]；2) 恶性肿瘤细胞引起血小板聚集功能、黏附与释放功能亢进 [<xref ref-type="bibr" rid="hanspub.37838-ref12">12</xref>]；3) 恶性肿瘤为消耗性疾病，机体为了修复损伤，骨髓会代偿性增生，新生血小板数目增加、体积较大 [<xref ref-type="bibr" rid="hanspub.37838-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.37838-ref14">14</xref>]；4) 通过恶性肿瘤细胞分泌、刺激增多的血小板释放转化生长因子，进而直接刺激部分肿瘤细胞的生长，而增殖的肿瘤组织又产生更多的促进骨髓巨核细胞生成的刺激因子，从而形成恶性循环 [<xref ref-type="bibr" rid="hanspub.37838-ref15">15</xref>]。</p></sec><sec id="s7"><title>3. 纤维蛋白原在恶性肿瘤诊断、监测、预后中的研究进展</title><p>纤维蛋白原是一种糖蛋白，分子量340 kD，由肝细胞合成并分泌。由两对α链、β链及γ组成，α及β肽链的N－端分别有一段称为纤维肽A及B的小肽，纤维肽A及B被凝血酶特异切除后，形成聚合网状的纤维蛋白单体 [<xref ref-type="bibr" rid="hanspub.37838-ref16">16</xref>]。纤维蛋白原主要参与机体的凝血过程。同时，也是一种急性时相反应蛋白，在糖尿病、急性传染病、肾病综合征、心脑血管等疾病中会反应性升高。随着人们对纤维蛋白原关注度的提高，发现血浆纤维蛋白原水平升高与多种恶性肿瘤预后不良有关 [<xref ref-type="bibr" rid="hanspub.37838-ref17">17</xref>]。Lee等人发现，癌症患者的血浆纤维蛋白原水平显著高于良性疾病患者，并且纤维蛋白原水平在复发或转移期间升高 [<xref ref-type="bibr" rid="hanspub.37838-ref18">18</xref>]。与此同时，越来越多的证据表明纤维蛋白原与癌症患者的肿瘤临床分期、血管生成、转移性扩散和对治疗的反应有关 [<xref ref-type="bibr" rid="hanspub.37838-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.37838-ref20">20</xref>]。王卉媛的研究报道肺癌患者的纤维蛋白原水平比健康人高，同时，也说明纤维蛋白原在对肺癌患者的诊断及预后，与疗效评估，复发，转移上有监测意义，有很好的临床应用价值 [<xref ref-type="bibr" rid="hanspub.37838-ref21">21</xref>]。李敏等研究发现，纤维蛋白原水平在胃癌患者中明显高于胃良性病变患者，而胃癌伴肝转移患者的纤维蛋白原水平也高于未转移患者。经过治疗后, 胃癌患者的纤维蛋白原水平较前明显降低 [<xref ref-type="bibr" rid="hanspub.37838-ref22">22</xref>]。史青苗等研究发现，肝细胞肝癌患者的血浆纤维蛋白原高于乙肝肝硬化患者, 并且随着TNM分期的增加纤维蛋白原值也在增加 [<xref ref-type="bibr" rid="hanspub.37838-ref23">23</xref>]。有文献报道，在乳腺癌患者中，高纤维蛋白原水平往往预示着生存期较差 [<xref ref-type="bibr" rid="hanspub.37838-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.37838-ref25">25</xref>]。因此，纤维蛋白原在肿瘤的发生和转移中起着重要作用，动态监测纤维蛋白原值可以为多种肿瘤的诊断和预后提供潜在帮助。</p></sec><sec id="s8"><title>4. D-二聚体在恶性肿瘤诊断、监测、预后中的研究进展</title><p>D-二聚体是纤维蛋白单体经活化因子XIII交联后，再经纤溶酶水解所产生的一种特异性降解产物，是一个特异性的纤溶过程标记物。它广泛应用于血栓性疾病、急性心肌梗死、脑梗死、炎症弥漫性血管内凝血的诊断和病情监测 [<xref ref-type="bibr" rid="hanspub.37838-ref26">26</xref>]。近年来，D-二聚体在恶性肿瘤诊治中也得到广泛应用。陈辰等发现，术前D-二聚体水平升高、TNM分期晚是影响非小细胞肺癌患者生存期的独立因素。术前D-二聚体水平测定可作为非小细胞肺癌预后预测的潜在指标, 具有一定的临床意义 [<xref ref-type="bibr" rid="hanspub.37838-ref27">27</xref>]。有研究报道，D-二聚体可作为胰腺癌监测预测因子，术前血浆D-二聚体异常的患者术后复发快，预后差，应加强监测，提供及时有效的干预 [<xref ref-type="bibr" rid="hanspub.37838-ref28">28</xref>]。林颖欣等研究87例转移性乳腺癌患者化疗前后血浆D-D水平，发现转移性乳腺癌患者的血浆D-二聚体水平随病情转归而波动，化疗后D-二聚体水平不仅能辅助疗效判断，对无进展生存期和预后也有一定预测作用，化疗后高D-二聚体水平者无进展生存期更短 [<xref ref-type="bibr" rid="hanspub.37838-ref29">29</xref>]。有日本学者发现，高水平D-二聚体可预测局部进展期胃癌切除患者的肿瘤复发和长期生存，术后D-二聚体水平升高的患者需仔细观察及行影像学检查，及时发现肿瘤复发 [<xref ref-type="bibr" rid="hanspub.37838-ref30">30</xref>]。赵乐等研究发现，术前食管癌组血清D-D水平显著高于健康组(p = 0.002)，术后两周开始接近正常水平，且D-二聚体水平随TNM分期的升高而上升，提示恶性肿瘤发生时常伴凝血及纤溶异常，表明D-二聚体检测可为食管癌病情程度及手术效果的判断提供一定帮助 [<xref ref-type="bibr" rid="hanspub.37838-ref31">31</xref>]。有研究报道，D-二聚体可以影响细胞信号系统，促进细胞增殖，刺激肿瘤细胞与内皮细胞的细胞黏附，影响血小板和细胞外基质，诱导肿瘤的生长和扩散 [<xref ref-type="bibr" rid="hanspub.37838-ref32">32</xref>]。总而言之，D-二聚体在肿瘤的诊断、病情监测、预后方面都发挥着作用。</p></sec><sec id="s9"><title>5. 展望</title><p>恶性肿瘤的发病率和死亡率逐年递增，人们开始关注恶性肿瘤患者的早诊早治。随着对恶性肿瘤患者凝血功能研究的深入，越来越多的证据表明恶性肿瘤凝血功能紊乱与肿瘤细胞的发生发展及复发转移密切相关。因此，凝血功能可作为监测恶性肿瘤转移、治疗疗效及预后的一项重要指标。然而，目前关于凝血紊乱在肿瘤生长、转移领域内的确切作用机制还不完全了解，尚需更多的实验研究阐述其作用机制。</p></sec><sec id="s10"><title>文章引用</title><p>张 跳,杨卫卫. 恶性肿瘤相关凝血功能的研究进展Advances in Research on Coagulation Function Associated with Malignant Tumors[J]. 临床医学进展, 2020, 10(09): 2180-2184. https://doi.org/10.12677/ACM.2020.109329</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.37838-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. &lt;br&gt;https://doi.org/10.3322/caac.21492</mixed-citation></ref><ref id="hanspub.37838-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">张雪菲, 张帅, 于雁. 凝血指标异常与非小细胞肺癌转移及预后的关系[J]. 现代肿瘤医学, 2016, 24(13): 2070-2072.</mixed-citation></ref><ref id="hanspub.37838-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">张学振, 陈国荣, 李君艳. 食管鳞癌患者凝血指标与临床病理特征的关系[J]. 山东医药, 2017, 57(22): 15-18.</mixed-citation></ref><ref id="hanspub.37838-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">朱小双, 孙轶华. 血小板在肿瘤转移中的研究进展[J]. 中国实验诊断学, 2020, 24(3): 522-525.</mixed-citation></ref><ref id="hanspub.37838-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">董超男, 翟文萍, 王雪野. 血小板介导肿瘤细胞生长和转移的机制研究进展[J]. 医学综述, 2020, 26(4): 695-699.</mixed-citation></ref><ref id="hanspub.37838-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Liu, Y.H., Liu, X.B., Xu, L., et al. (2018) Magnetic Resonance Imaging Evaluation of Treatment Efficacy and Prognosis for brain Metastases in Lung Cancer Patients after Radiotherapy: A Preliminary Study. Thoracic Cancer, 9, 865-873.  
&lt;br&gt;https://doi.org/10.1111/1759-7714.12763</mixed-citation></ref><ref id="hanspub.37838-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">李延青. 炎症性肠病癌变的内镜筛查及化学预防[J]. 中国实用内科杂志, 2018, 38(9): 780-783.</mixed-citation></ref><ref id="hanspub.37838-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">黄远玲, 李纯团, 王少雄, 郑艳, 朱雄鹏. 胃癌患者凝血功能、D二聚体、血小板计数的变化与肿瘤临床特征的关系[J]. 血栓与止血学, 2019, 25(6): 906-908+912.</mixed-citation></ref><ref id="hanspub.37838-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">申太峰, 王悦, 杨帆. 子宫颈浸润癌与血小板增多的临床分析[J]. 中国妇产科临床杂志, 2014, 15(4): 295-297.</mixed-citation></ref><ref id="hanspub.37838-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Burger, J.A. and Kipps, T.J. (2006) CXCR4: A Key Receptor in the Crosstalk between Tumor Cells and Their Microenvironment. Blood, 107, 1761-1767. &lt;br&gt;https://doi.org/10.1182/blood-2005-08-3182</mixed-citation></ref><ref id="hanspub.37838-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Nagata, S. and Fukunaga, R. (1993) Granulocyte Colony-Stimulating Factor Receptor and Its Related Receptors. Growth Factors, 8, 99-107. &lt;br&gt;https://doi.org/10.3109/08977199309046930</mixed-citation></ref><ref id="hanspub.37838-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">任莲萍，沈晨辉. 肿瘤相关性血管疾病[J]. 国外医学肿瘤学分册，1998, 25(2): 78-79.</mixed-citation></ref><ref id="hanspub.37838-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">孙旺远, 高蔚, 翁婷, 王丽芳, 沈威, 施斌. 肺癌患者血小板参数的临床意义[J]. 中国校医, 2017, 31(5): 365-367.</mixed-citation></ref><ref id="hanspub.37838-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">张永瑞, 白泽坤, 翟丽. 肿瘤患者血小板参数显示不全的原因分析[J]. 国际检验医学杂志, 2018, 39(20): 2531-2534.</mixed-citation></ref><ref id="hanspub.37838-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Franco, A.T., Corken, A. and Ware, J. (2015) Platelets at the Interface of Thrombosis, Inflammation, and Cancer. Blood, 126, 582-588. &lt;br&gt;https://doi.org/10.1182/blood-2014-08-531582</mixed-citation></ref><ref id="hanspub.37838-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">朱建华. 肺癌患者化疗前后凝血、纤溶功能相关指标和血小板计数变化分析[J]. 中国基层医药, 2016, 23(19): 3014-3017.</mixed-citation></ref><ref id="hanspub.37838-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Perisanidis, C., Psyrri, A., Cohen, E.E., Engelmann, J., Heinze, G., Perisanidis, B., Stift, A., Filipits, M., Kornek, G. and Nkenke, E. (2015) Prognostic Role of Pretreatment Plasma Fibrinogen in Patients with Solid Tumors: A Systematic Review and Meta-Analysis. Cancer Treatmentreviews, 41, 960-970. 
&lt;br&gt;https://doi.org/10.1016/j.ctrv.2015.10.002</mixed-citation></ref><ref id="hanspub.37838-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Lee, S.E., Lee, J.H., Ryu, K.W., Nam, B.-H., Cho, S.J., Lee, J.Y., Kim, C.G., Choi, I.J., Kook, M.-C., Park, S.R. and Kim, Y.-W. (2012) Preoperative Plasma Fibrinogen Level Is a Useful Predictor of Adjacent Organ Involvement in Patients with Advanced Gastric Cancer. Journal of Gastric Cancer, 12, 81-87. 
&lt;br&gt;https://doi.org/10.5230/jgc.2012.12.2.81</mixed-citation></ref><ref id="hanspub.37838-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Mark, J.J., McGonigle, N.C., McAnespie, M., Cran, G.W. and Graham, A.N. (2006) Plasma Fibrinogen and Serum C-Reactive Protein Are Associated with Non-Small Cell Lung Cancer. Lung Cancer, 53, 97-101. 
&lt;br&gt;https://doi.org/10.1016/j.lungcan.2006.03.012</mixed-citation></ref><ref id="hanspub.37838-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, J., Zhao, M.F., Jin, B., Yu, P., Hu, X.J., Teng, Y., Zhang, J.D., Luo, Y., Zhang, L.J., Zheng, S., Zhou, Q.Y., Li, H.M., Liu, Y.P. and Qu, X.J. (2012) Tumor Response and Survival in Patients with Advanced Non-Small-Cell lung Cancer: The Predictive Value of Chemotherapy-Induced Changes in Fibrinogen. BMC Cancer, 12, Article No. 330. 
&lt;br&gt;https://doi.org/10.1186/1471-2407-12-330</mixed-citation></ref><ref id="hanspub.37838-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">王卉媛. 凝血常规检查在肺癌患者中的应用价值分析[J]. 中国医药指南, 2019, 17(32): 18-19.</mixed-citation></ref><ref id="hanspub.37838-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">李敏, 綦晓龙, 唐国富, 李厚泽. D-二聚体、纤维蛋白原及其降解产物对胃癌诊断价值分析[J]. 实用医院临床杂志, 2019, 16(2): 101-103.</mixed-citation></ref><ref id="hanspub.37838-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">史青苗, 薛晨, 何玉婷, 任志刚, 余祖江. 肝细胞肝癌患者血浆纤维蛋白原、D-二聚体改变的临床意义[J]. 河南医学研究, 2018, 27(23): 4232-4234.</mixed-citation></ref><ref id="hanspub.37838-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Wen, J.H., Yang, Y.N., Ye, F., Huang, X.J., Li, S.J., Wang, Q. and Xie, X.M. (2015) The Preoperative Plasma Fibrinogen Level Is an Independent Prognostic Factor for Overall Survival of Breast Cancer Patients Who Underwent Surgical Treatment. The Breast, 24, 745-750. &lt;br&gt;https://doi.org/10.1016/j.breast.2015.09.007</mixed-citation></ref><ref id="hanspub.37838-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Sabine, K.-P., Uwe, L., Stojakovic, T., Pichler, M., Gerger, A., Kapp, K.S. and Langsenlehner, T. (2015) An Elevated Preoperative Plasma Fibrinogen Level Is Associated with Poor Disease-Specific and Overall Survival in Breast Cancer Patients. Breast, 24, 667-672. &lt;br&gt;https://doi.org/10.1016/j.breast.2015.08.003</mixed-citation></ref><ref id="hanspub.37838-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">魏炎, 李锴男, 毕经旺. 消化系统肿瘤中纤维蛋白原及D-二聚体的表达及临床价值[J]. 生物技术通讯, 2016, 27(4): 542-544.</mixed-citation></ref><ref id="hanspub.37838-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">陈辰, 李利亚. 术前血小板、血浆纤维蛋白原及D-二聚体水平与小细胞肺癌预后的相关性分析[J]. 现代肿瘤医学, 2019, 27(7): 1148-1153.</mixed-citation></ref><ref id="hanspub.37838-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">王文闻, 肖燕, 王琦. 血浆D-二聚体在胰腺癌患者中的临床意义[J]. 中国肿瘤外科杂志, 2020, 12(3): 219-222.</mixed-citation></ref><ref id="hanspub.37838-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">林颖欣, 庞丹梅, 胡倩, 段海波, 陈秀云. D-二聚体水平与转移性乳腺癌化疗效果及预后的关系[J]. 广东医科大学学报, 2019, 37(6): 700-703.</mixed-citation></ref><ref id="hanspub.37838-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Hara, K., Aoyama, T., Hayashi, T., Nakazono, M., Nagasawa, S., Shimoda, Y., Kumazu, Y., Numata, M., Yamada, T., Tamagawa, H., Shiozawa, M., Morinaga, S., Yukawa, N., Rino, Y., Masuda, M., Ogata, T. and Oshima, T. (2020) Postoperative D-Dimer Elevation Affects Tumor Recurrence and the Long-Term Survival in Gastric Cancer Patients Who Undergo Gastrectomy. International Journal of Clinical Oncology, 25, 584-594. 
&lt;br&gt;https://doi.org/10.1007/s10147-019-01603-x</mixed-citation></ref><ref id="hanspub.37838-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">赵乐, 杨国栋, 常永超. D-二聚体联合CA19-9、SCC对食管癌的诊断价值[J]. 实验与检验医学, 2019, 37(5): 882-884.</mixed-citation></ref><ref id="hanspub.37838-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Liang, Y.X., He, D.L., Wu, L.L., Ding, X.W., Wang, X.N., Wang, B.G., Zhang, R.P. and Liang, H. (2018) Elevated Preoperative Plasma D-Dimer Dose Not Adversely Affect Survival of Gastric Cancer after Gastrectomy with Curative Intent: A Propensity Score Analysis. Chinese Journal of Cancer Research, 30, 254-262. 
&lt;br&gt;https://doi.org/10.21147/j.issn.1000-9604.2018.02.08</mixed-citation></ref></ref-list></back></article>